Wiggin and Dana Advises Alligator Bioscience AB in Licensing Agreement with Janssen Biotech, Inc.

August 27, 2015

Stamford – Wiggin and Dana client Alligator Bioscience AB, a privately held Swedish biotech company developing innovative antibody-based immunotherapies for the treatment of cancer, recently announced a license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement, Alligator grants Janssen an exclusive, worldwide license to develop and commercialize Alligator's clinical candidate ADC-1013. Alligator will receive an up-front payment and potentially certain development, regulatory and commercial milestone payments, up to US$700 million, in addition to tiered royalties on worldwide net sales.

The Wiggin and Dana team involved in this transaction consisted of Corporate Partners James F. Farrington, Jr., Mark S. Kaduboski and Sapna W. Palla, and Corporate Associates Monica A. Kolinsky, Tobias F. Bannon, III, and Adrienne M. de la Rosa.

For more information about this transaction, please click here to view Alligator's press release and click here to view Janssen's press release.